Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?-Reference-Cited by-同舟云学术

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

Published:2022-02 Issue: Volume:170 Page:103597
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Fanale Daniele^ORCID,Corsini Lidia Rita,Scalia Raimondo,Brando Chiara,Cucinella Alessandra^ORCID,Madonia Giorgio^ORCID,Dimino Alessandra,Filorizzo Clarissa^ORCID,Barraco Nadia,Bono Marco^ORCID,Fiorino Alessia,Magrin Luigi,Sciacchitano Roberta,Perez Alessandro,Russo Tancredi Didier Bazan,Pantuso Gianni,Russo Antonio^ORCID,Bazan Viviana

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference191 articles.

1. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK;Al-Batran;J. Clin. Oncol.,2019

2. Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors;Altavilla;Oncol. Rep.,2010

3. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer;André;N. Engl. J. Med.,2020

4. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601);Antill;Ann. Oncol.,2019

5. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial;Antill;J. Immunother. Cancer,2021

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors;CHINESE J CANCER RES;2024

2. Immunotherapy for Ovarian Cancer: Disappointing or Promising?;Molecular Pharmaceutics;2024-01-17

3. Advances in immunotyping of colorectal cancer;Frontiers in Immunology;2023-10-09

4. Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?;Critical Reviews in Oncology/Hematology;2023-10

5. Construction of a prognostic signature associated with liver metastases for prognosis and immune response prediction in colorectal cancer;Frontiers in Oncology;2023-07-26